ArticlePloS one2020
Impact of a candidate vaccine on the dynamics of salmon lice (Lepeophtheirus salmonis) infestation and immune response in Atlantic salmon (Salmo salar L.).
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Vaccination modality and injection site influence the immune response and protection against sea liceBiochemistry and biophysics reports · 2026Article
- Prime-boost vaccination with chimeric antigens adjuvanted in Montanide™ ISA50 V2 confers protection against experimentalFrontiers in immunology · 2025Article
- Transforming Aquaculture through Vaccination: A Review on Recent Developments and Milestones.Vaccines · 2024Review
- A Proof-of-Concept Study to Develop a Peptide-Based Vaccine against Salmon Lice Infestation in Atlantic Salmon (Vaccines · 2024Article
- Monoclonal antibody generated against Nile tilapia (Fish and shellfish immunology reports · 2023Article
- Identification and characterization of two salmon louse heme peroxidases and their potential as vaccine antigens.iScience · 2023Article
- Article
- Applying genetic technologies to combat infectious diseases in aquaculture.Reviews in aquaculture · 2023Review
- The Bm86 Discovery: A Revolution in the Development of Anti-Tick Vaccines.Pathogens (Basel, Switzerland) · 2023Article
- Dual RNA-Seq Analysis Reveals Transcriptome Effects during the Salmon-Louse Interaction in Fish Immunized with Three Lice Vaccines.Vaccines · 2022Article
- Article
- Protective Immunization of Atlantic Salmon (SVaccines · 2021Article
- Article
- State-of-the-Art Vaccine Research for Aquaculture Use: The Case of Three Economically Relevant Fish Species.Vaccines · 2021Review
- To React or Not to React: The Dilemma of Fish Immune Systems Facing Myxozoan Infections.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection with parasitic copepod salmon louse Lepeophtheirus salmonis, represents one of the most important limitations to sustainable Atlantic salmon (Salmo salar L.) farming today in the North Atlantic region. The parasite exerts negative impact on health, growth and welfare of farmed fish as well as impact on wild salmonid populations. It is therefore central to ensure continuous low level of salmon lice with the least possible handling of the salmon and drug use. To address this, vaccination is a cost-effective and environmentally friendly control approach. In this study, efficacy of a vaccine candidate, containing a peptide derived from ribosomal protein P0, was validated post infestation with L. salmonis, at the lab-scale. The sampling results showed good potential of the vaccine candidate when administered intraperitoneally in the host, in reducing the ectoparasite load, through reduction of adult female lice counts and fecundity and with greater presumptive effect in F1 lice generation. The sampling results correlated well with the differential modulation of pro-inflammatory, Th1, Th2 and T regulatory mediators at the transcript level at different lice stages. Overall, the results supports approximately 56% efficacy when administered by intraperitoneal injection. However, additional validation is necessary under large-scale laboratory trial for further application under field conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.